An editorial notes that this study addresses an important gap in the use of stroke prevention therapy for patients with AF in primary care, a setting which will likely continue to encounter a growing AF burden. It adds that although appropriate use of antithrombotic therapy is increasing, additional simple and cost-effective strategies are needed to demonstrate an even higher use of DOAC in eligible patients, particularly those at moderate risk, as well as minimising overtreatment and reducing practice variations.